Acyltransferase Activity and Protein Quantification

High-Sensitivity Acyltransferase Activity and Protein Quantification Services for Lipid Metabolism Research, Drug Discovery, and Bioprocess Development

Acyltransferases represent a large and diverse family of enzymes that catalyse the transfer of acyl groups from donor molecules (typically acyl-CoA or acyl-ACP) to a wide variety of acceptor substrates, including glycerol-3-phosphate, lysophosphatidic acid, diacylglycerol, sterols, and proteins. These enzymes are pivotal in lipid biosynthesis, membrane remodelling, energy storage, and signal transduction. Dysregulation of acyltransferase activity is implicated in metabolic disorders, cancer, and cardiovascular diseases, making them significant therapeutic targets and biomarkers. The accurate and comprehensive characterisation of acyltransferases—encompassing catalytic activity, substrate specificity, kinetic parameters, protein abundance, and inhibitor sensitivity—is essential for understanding metabolic pathways, validating drug targets, and optimising biotechnological production of lipids and lipid-derived compounds. Our specialised detection platform offers a fully validated suite of biochemical, radiometric, mass spectrometric, and cell‑based assays tailored to all major acyltransferase families, delivering the high‑precision, regulatory‑ready data that clients require for research, drug development, and quality assurance.

Scientific, Clinical, and Biotechnological Rationale for Acyltransferase Analysis

Clients seeking acyltransferase detection services are motivated by a range of strategic objectives. In lipid metabolism and systems biology research, the primary need is to quantify the activity of specific acyltransferase isoforms (e.g., DGAT1, DGAT2, GPAT, AGPAT, LPCAT, LCAT, ACAT) to understand flux through lipid synthesis pathways, to identify regulatory nodes, and to study the effects of genetic or pharmacological perturbations. In drug discovery and pharmacology, measuring the inhibitory potency of novel compounds against target acyltransferases is critical for identifying selective and potent candidates for the treatment of obesity, fatty liver disease, atherosclerosis, and cancer. In biopharmaceutical manufacturing, monitoring acyltransferase activity is important for ensuring the consistency of lipid-based formulations and for quality control of recombinant enzymes used as biocatalysts. In nutritional and dietary research, acyltransferase responses to dietary fats, fatty acids, and other nutrients are studied to understand metabolic adaptation and to evaluate the efficacy of functional foods. In quality control of enzyme reagents, verifying the specific activity, purity, and stability of recombinant acyltransferase standards is essential for assay development and diagnostic kit production. In regulatory submissions, comprehensive data on enzyme activity, selectivity, and stability are required for the approval of novel therapeutics and biotechnological products. Our service is architected to address these diverse needs with a flexible, ISO 17025‑accredited analytical framework that adapts to the specific acyltransferase family (e.g., DGAT, GPAT, AGPAT, LPCAT, LCAT, ACAT), sample matrix (cell lysates, tissue homogenates, purified recombinant proteins, microsomes, subcellular fractions), and client's research or regulatory context.

Integrated Analytical Platform for Holistic Acyltransferase Characterisation

Our analytical platform comprises five interconnected modules that collectively deliver a comprehensive evaluation of acyltransferase quality, activity, and specificity. The Activity Quantification Module employs a range of validated assays, including radiometric assays using ¹⁴C‑labelled or ³H‑labelled acyl-CoA donors for maximum sensitivity, fluorometric assays using labelled acceptor substrates (e.g., NBD‑labelled lipids) for high‑throughput screening, and mass spectrometric assays (LC‑MS/MS) that directly quantify the formation of lipid products (e.g., triacylglycerols, phosphatidic acid, lysophosphatidylcholine, cholesterol esters) with mass accuracy < 2 ppm. We determine the specific activity (U/mg protein) with precision within ±2% RSD and a limit of detection (LOD) as low as 0.001 U/mL. For detailed kinetic characterisation, we calculate Michaelis‑Menten parameters (K_m for the acyl‑CoA donor and the acceptor substrate, V_max, k_cat) and inhibition constants (IC₅₀, K_i) for a panel of known inhibitors (e.g., DGAT inhibitors, ACAT inhibitors) and test compounds, with 95% confidence intervals typically within ±5%. The Substrate Specificity and Acceptor Profiling Module uses a custom panel of acyl‑CoA species (C8:0, C12:0, C14:0, C16:0, C18:1, C18:2, C20:4) and acceptor substrates (e.g., glycerol‑3‑phosphate, lysophosphatidic acid, diacylglycerol, cholesterol, lysophosphatidylcholine) to generate a specificity fingerprint that reveals the enzyme's preference for acyl chain length and unsaturation, as well as acceptor selectivity. The Protein Quantitation and Isoform Module uses ELISA with isoform‑specific monoclonal antibodies (e.g., anti‑DGAT1, anti‑DGAT2, anti‑AGPAT2, anti‑LCAT) to quantify protein abundance, providing LOQs of 0.05 ng/mg of total protein and inter‑assay precision < 5%. For absolute quantitation and isoform discrimination, we use LC‑MS/MS‑based targeted proteomics (PRM) with stable isotope‑labelled peptide standards, achieving LOQs in the low fmol/mg range and enabling the simultaneous quantitation of multiple acyltransferase isoforms in a single run. The Inhibitor and Drug Interaction Module evaluates the effect of test compounds on acyltransferase activity using the primary activity assay, providing mechanism‑of‑action analysis (competitive, uncompetitive, or mixed) and binding affinity measurements by surface plasmon resonance (SPR) or isothermal titration calorimetry (ITC), with K_D values in the low nM range. The Stability and Formulation Module subjects the enzyme to accelerated aging conditions (temperatures from 2°C to 40°C, pH 4‑9, and various ionic strengths) and monitors residual activity, aggregation (by SEC‑HPLC), and conformational integrity (by CD spectroscopy) over time. Using Arrhenius modelling and deactivation kinetics, we predict shelf‑life and identify critical degradation pathways (e.g., deamidation, oxidation, aggregation). All modules are validated with reference acyltransferase standards (commercial or in‑house) and include rigorous quality controls (system suitability, blank subtraction, and replicate analyses).

Unmatched Analytical Sensitivity, Specificity, and Mechanistic Depth

Our platform consistently delivers performance that surpasses typical industry and academic standards. In activity assays, we achieve signal‑to‑noise ratios > 300:1 at the LOD, with linearity over four orders of magnitude and Z’‑factors consistently > 0.8, making our assays highly robust for high‑throughput screening. Our kinetic fitting software uses global non‑linear regression to provide precise estimates of K_m and V_max, with residual errors < 2%. For protein quantitation by PRM, our chromatographic gradient resolves isoform‑specific peptides with retention time reproducibility < 0.5% RSD and peak area precision < 3%. In substrate specificity studies, our UHPLC‑MS/MS product quantification provides mass accuracy < 2 ppm and enables the confident identification of lipid products, with quantification limits in the low nM range. In inhibitor studies, we perform full dose‑response curves with at least 8 concentrations in triplicate, and we provide Dixon plots and Cornish‑Bowden analyses to determine the mechanism of inhibition. Additionally, we offer isothermal titration calorimetry (ITC) to measure the binding thermodynamics of inhibitors, providing ΔH, ΔS, and binding stoichiometry with precision within ±2%. For clients requiring detailed structural insight, we perform hydrogen‑deuterium exchange mass spectrometry (HDX‑MS) to map ligand‑binding sites and conformational changes. This multi‑dimensional data set enables our clients to not only quantify acyltransferase activity but also to understand the molecular basis of substrate recognition, lipid product specificity, and inhibition, facilitating the rational design of more selective drugs and efficient industrial enzymes.

Distinctive Advantages of Our Acyltransferase Detection Service

Our service provides several unique benefits that directly address client challenges. First, we have developed matrix‑specific sample preparation protocols for a wide variety of acyltransferase sources—including cell lysates, tissue homogenates, microsomal fractions, mitochondrial fractions, and purified recombinant proteins—that effectively preserve enzyme activity and protein integrity, achieving recoveries > 95% for all tested matrices. Second, we maintain a comprehensive reference library of acyltransferase isoforms (DGAT1, DGAT2, GPAT1-4, AGPAT1-6, LPCAT1-4, LCAT, ACAT1, ACAT2), their known substrates, and a curated list of inhibitors, enabling rapid method setup and confident benchmarking. Third, we offer a rapid screening service using a microplate‑based fluorometric assay that provides semi‑quantitative activity data within 2 hours of sample receipt—ideal for high‑throughput screening of compound libraries, genetic screens, or nutritional studies. Fourth, our customised kinetic and inhibition studies can be tailored to simulate physiological conditions, including the presence of lipid vesicles, serum proteins, and relevant cofactors. Fifth, we provide integrated data interpretation that links enzyme activity, isoform abundance, and inhibition profiles to biological or industrial outcomes (e.g., lipid accumulation, drug efficacy, biocatalytic yield), enabling clients to make informed decisions on candidate selection and process optimisation. Sixth, all our methods comply with ICH M10, FDA, and EMA guidelines on bioanalytical method validation, and we supply full validation dossiers (specificity, linearity, accuracy, precision, LOD, LOQ, robustness) along with detailed SOPs, ensuring that our data are readily accepted by regulatory authorities. Our team of lipid biochemists, enzymologists, and pharmacologists provides consultative interpretation, helping clients to design follow‑up experiments, predict in vivo efficacy, and support regulatory submissions.

Advanced Data Integration, Predictive Modeling, and Reporting

Our reporting transforms analytical data into strategic decision‑making knowledge. We deliver a comprehensive final report that includes: (i) an executive dashboard with key metrics (specific activity, K_m, IC₅₀, K_i, isoform abundance, and acyl chain preference) presented as concise scorecards; (ii) a detailed analytical section containing raw data, calibration curves, kinetic fits, and chromatograms; (iii) a statistical comparison of samples against reference standards or historical data, with p‑values and confidence intervals; and (iv) an interpretive narrative that contextualises the results—for example, explaining how a low IC₅₀ indicates a potent and selective acyltransferase inhibitor, or how a specific acyl‑CoA preference may influence the enzyme's role in different metabolic pathways. For clients with multiple compounds, samples, or time‑points, we provide multivariate analysis (PCA, PLS‑DA) to identify the most influential parameters and to guide selection. We also offer predictive models that estimate in vivo lipid metabolism or drug efficacy based on in vitro acyltransferase data, using our internally developed machine learning tools. All raw data files (e.g., .xlsx, .raw, .cdf) are supplied to ensure full transparency and re‑analysis capability.

Broad Applications Across Lipid Biology, Drug Discovery, and Biopharmaceutical Manufacturing

The versatility of our acyltransferase detection service spans a wide range of sectors. In lipid biology and metabolic research, our assays are critical for understanding the regulation of lipid synthesis, storage, and secretion. In pharmaceutical and biotech R&D, we support target validation, lead optimisation, and selectivity profiling of novel acyltransferase modulators. In biopharmaceutical manufacturing, we quantify acyltransferase activity to monitor the quality of lipid‑based products and recombinant enzyme preparations. In nutritional and dietary research, we evaluate the impact of dietary components on acyltransferase activity. In academic research, our comprehensive profiling supports publication‑quality studies on enzyme mechanism, regulation, and structure‑function relationships. In contract research organisations (CROs), our services provide robust data to support regulatory submissions. Our ability to tailor the analytical package to the specific acyltransferase family, sample type, and regulatory framework ensures that we serve a diverse global clientele with scientific rigour and practical relevance.

Commitment to Innovation, Quality, and Client Partnership

We are dedicated to advancing acyltransferase analytics through continuous technological improvement. Our current R&D includes the development of microfluidic‑based single‑cell activity assays for ultra‑sensitive detection, and the application of machine learning algorithms to predict substrate specificity and inhibitor potency from protein sequence data. We actively participate in inter‑laboratory proficiency testing for enzyme activity and lipid analysis, and we contribute to the development of reference standards for lipid metabolising enzymes. Our quality management system is ISO 9001 and ISO 17025 certified, and we follow GLP for all regulatory studies. We offer flexible engagement models—from single‑sample analysis to multi‑year collaborative projects—with dedicated project managers, volume discounts, and priority handling for time‑sensitive samples. Our global logistics provide specialised shipping kits (with stabilising buffers and temperature control) to preserve enzyme activity during transit. Turnaround times range from 1 business day for rapid screening to 14 business days for comprehensive kinetic, proteomic, and inhibition profiling. We maintain open communication, providing preliminary results upon request and final reports with expert commentary. Our success is measured by the confidence our clients have in their data and their ability to advance lipid research, drug development, and biopharmaceutical quality. We invite you to partner with us to unlock the full potential of your acyltransferase research.

In summary, our acyltransferase detection service delivers a comprehensive, precise, and application‑oriented analytical solution that integrates activity quantification, isoform‑specific protein quantitation, substrate specificity profiling, inhibitor screening, and stability evaluation. By combining advanced instrumentation with deep expertise in lipid enzymology and translational science, we empower our clients to understand lipid metabolism, develop novel therapeutics, and ensure product quality. We look forward to supporting your acyltransferase analysis needs with our state‑of‑the‑art analytical platform.